GWAS meta-analysis identifies 89 loci for mitral valve prolapse and genetic links to hypertrophic cardiomyopathy.

This meta-analysis of genome-wide association studies (GWAS) examined the genetic architecture of mitral valve prolapse (MVP) and its relationship to other cardiomyopathies. The analysis included 21,517 cases of MVP within a total sample size of over 2.2 million individuals. Researchers sought to identify causal genes, pathways, and genetic correlations, specifically focusing on the link between MVP and hypertrophic cardiomyopathy.

The study identified 89 genomic risk loci for MVP, of which 72 represented novel findings. Known gene associations were successfully replicated, particularly those involving TGF-beta signaling and extracellular matrix biology. Furthermore, several MVP risk loci were found to exhibit pleiotropy, showing associations with cardiomyopathies, especially hypertrophic cardiomyopathy.

A significant genetic correlation between MVP and hypertrophic cardiomyopathy was demonstrated, though specific effect sizes or p-values were not reported in the provided data. The study noted that the genetic architecture of MVP and the factors explaining why only some individuals develop adverse outcomes remain poorly understood. No adverse events or safety data were reported, as this was a genetic association study rather than a clinical trial.

Key limitations include the incomplete understanding of genetic factors driving adverse outcomes in MVP. As this is an observational genetic study, the findings describe statistical associations and do not establish causality. These results inform the genetic landscape of MVP but do not currently alter standard clinical practice or management recommendations for patients.